论著

影响癌性肠梗阻病人预后的多因素分析

展开
  • 上海交通大学医学院附属第九人民医院普外科,上海 200011

收稿日期: 2020-05-14

  网络出版日期: 2022-09-20

基金资助

浦东新区卫生和计划生育委员会卫生计生科研项目(PW2018D-01)

Multivariate analysis of prognosis of patients with malignant bowel obstruction

Expand
  • Department of General Surgery, Shanghai Ninth People′s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China

Received date: 2020-05-14

  Online published: 2022-09-20

摘要

目的:多因素分析影响癌性肠梗阻(malignant bowel obstruction, MBO)病人预后的危险因素,构建MBO病人生存期预测的列线图模型。方法:回顾性分析我院2013年6月至2019年6月 203例MBO病人的临床资料及随访。结果:随访143例(70.4%)病人。单因素分析结果显示,性别、年龄、血小板、C反应蛋白、总蛋白含量、合并症数量、使用生长抑素治疗、肠内营养和肠外营养治疗、住院时间与MBO病人的生存无相关性。肿瘤TNM分期晚(P<0.001)、肿瘤继发转移(P<0.001)、贫血(P=0.001)、低白蛋白(P<0.001)、高白细胞(P=0.023)、非手术治疗(P=0.013)、生活质量评分低(P<0.001)以及肝功能差[包括高丙氨酸转氨酶(P=0.023)、高天冬氨酸转氨酶(P=0.005)]等因素与预后差有关。多因素分析显示,肿瘤分期(P=0.003)、白蛋白水平(P=0.001)是影响MBO病人预后的独立危险因素。采用TNM晚期、继发肿瘤以及血红蛋白低和白蛋白低4个指标构建的列线图。通过40例病人3~12个月的内部预测生存期,结果良好。结论:构建列线图和预后分析显示,MBO病人不良的主要因素是肿瘤晚期以及全身营养不良。

本文引用格式

程威, 黄雨桦, 王剑, 李幼生 . 影响癌性肠梗阻病人预后的多因素分析[J]. 外科理论与实践, 2022 , 27(04) : 340 -345 . DOI: 10.16139/j.1007-9610.2022.04.013

Abstract

Objective To analyze the risk factors for prognosis of patients with malignant bowel obstruction (MBO) using multiple factors, and establish the nomogram model for predicting the survival of patients with MBO. Methods The clinical data of 203 patients with MBO from June 2013 to June 2019 who were followed up in our hospital were analyzed retrospectively. Results A total of 143 (70.4%) patients have been followed up. It was shown with univariate analysis that indexes of gender, age, platelet, C-reactive protein, and total protein levels, comorbidities, the treatment with somatostatin, enteral nutrition, and parenteral nutrition, length of hospital were not related to the survival of patients with MBO. There were some factors including late TNM stage of tumor (P<0.001), tumor metastasis (P<0.001), anemia (P=0.001), lower albumin (P<0.001), higher white blood cell(P=0.023), non-surgical treatment(P=0.013), low quality of life score (P<0.001) and poor liver function [including high alanine aminotransferase (P=0.023), high aspartate aminotransferase (P=0.005)] which related with poorer prognosis in patients with MBO. Multivariate analysis showed that tumor stage (P=0.003) and albumin level(P=0.001) were independent risk factors affecting the prognosis of MBO. Nomogram was constructed using 4 indexes including late TNM stage, tumor metastasis, lower hemoglobin and lower albumin. It was indicated that the results of internal prognosis were better for the prediction of survival of 3 to 12 months of 40 cases. Conclusions The study on poor prognosis of patients with MBO combined with nomogram showed that both late stage of tumor and malnutrition were main factors.

参考文献

[1] Jacquet P, Jelinek JS, Steves MA, et al. Evaluation of computed tomography in patients with peritoneal carcinomatosis[J]. Cancer, 1993, 72(5):1631-1636.
[2] Ripamonti C, Twycross R, Baines M, et al. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer[J]. Support Care Cancer, 2001, 9(4):223-233.
[3] Selby D, Wright F, Stilos K, et al. Room for improvement? a quality-of-life assessment in patients with malignant bowel obstruction[J]. Palliat Med, 2010, 24(1):38-45.
[4] Krouse RS. The international conference on malignant bowel obstruction: a meeting of the minds to advance palliative care research[J]. J Pain Symptom Manage, 2007, 34(1 Suppl):S1-S6.
[5] Kim JS, Hur H, Min BS, et al. Oncologic outcomes of self-expanding metallic stent insertion as a bridge to surgery in the management of left-sided colon cancer obstruction: comparison with nonobstructing elective surgery[J]. World J Surg, 2009, 33(6):1281-1286.
[6] Ansaloni L, Andersson RE, Bazzoli F, et al. Guidelenines in the management of obstructing cancer of the left colon: Consensus Conference of the World Society of Emergency Surgery (WSES) and Peritoneum and Surgery (PnS) Socie-ty[J]. World J Emerg Surg, 2010, 5:29.
[7] Morris EJ, Taylor EF, Thomas JD, et al. Thirty-day postoperative mortality after colorectal cancer surgery in England[J]. Gut, 2011, 60(6):806-813.
[8] Krouse RS. Malignant bowel obstruction[J]. J Surg Oncol, 2019, 120(1):74-77.
[9] Ho KM, Chan KM, Kwok SY, et al. Colonic self-expan-ding metal stent (SEMS) as a bridge to surgery in left-sided malignant colonic obstruction: an 8-year review[J]. Surg Endosc, 2017, 31(5):2255-2262.
[10] Rodrigues-Pinto E, Morais R, Coelho C, et al. Bridge-to-surgery versus emergency surgery in the management of left-sided acute malignant colorectal obstruction - efficacy, safety and long-term outcomes[J]. Dig Liver Dis, 2019, 51(3):364-372.
[11] Anthony T, Baron T, Mercadante S, et al. Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction[J]. J Pain Symptom Manage, 2007,(1 Suppl):S49-S59.
[12] 顾晋. 肿瘤性肠梗阻的诊断和治疗[J]. 中国实用外科杂志, 2008, 28(9):703-706.
[13] Tuca A, Guell E, Martinez-Losada E, et al. Malignant bowel obstruction in advanced cancer patients: epidemio-logy, management, and factors influencing spontaneous resolution[J]. Cancer Manag Res, 2012, 4:159-169.
[14] Arezzo A, Balague C, Targarona E, et al. Colonic stenting as a bridge to surgery versus emergency surgery for malignant colonic obstruction: results of a multicentre randomised controlled trial(ESCO trial)[J]. Surg Endosc, 2017, 31(8):3297-3305.
[15] Hoppenot C, Peters P, Cowan M, et al. Malignant bowel obstruction due to uterine or ovarian cancer: are there differences in outcome?[J]. Gynecol Oncol, 2019, 154(1):177-182.
[16] Frago R, Ramirez E, Millan M, et al. Current management of acute malignant large bowel obstruction: a systematic review[J]. Am J Surg, 2014, 207(1):127-138.
[17] 江志伟, 黎介寿, 李宁, 等. 奥曲肽治疗晚期癌性肠梗阻的作用[J]. 医学研究生学报, 2007, 20(10):1044-1046.
[18] Currow DC, Quinn S, Agar M, et al. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction[J]. J Pain Symptom Manage, 2015, 49(5):814-821.
[19] Mercadante S. Octreotide for malignant bowel obstruction: commentary on Currow et al[J]. J Pain Symptom Manage, 2015, 49(5):813.
[20] Chi DS, Phaeton R, Miner TJ, et al. A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer[J]. Oncologist, 2009, 14(8):835-839.
[21] Cousins SE, Tempest E, Feuer DJ. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer[J]. Cochrane Database Syst Rev, 2016(1):CD002764.
[22] Bento JH, Bianchi ET, Tustumi F, et al. Surgical ma-nagement of malignant intestinal obstruction: outcome and prognostic factors[J]. Chirurgia (Bucur), 2019, 114(3):343-351.
[23] Baumgartner JM, Marmor R, Hsu A, et al. Obstruction-free survival following operative intervention for malignant bowel obstruction in appendiceal cancer[J]. Ann Surg Oncol, 2019, 26(11):3611-3617.
[24] Stein SL. Expert commentary on malignant bowel obstruction[J]. Dis Colon Rectum, 2019, 62(9):1031-1032.
文章导航

/